[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-gastric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-gastric-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,40,75,102,130,163,192,218,244,266,288,314,336,365,392,412,432,460],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100630349","a-multicentre-observational-cross-sectional-study-of-the-gastric-precancerous-epithelial-pathway-using-high-definition-endoscopy-and-histopathology-in-india-100630349",false,"NCT07486518","A Multicentre Observational Cross-Sectional Study of The Gastric Precancerous Epithelial Pathway Using High-Definition Endoscopy And Histopathology In India","IND-PREP","1. Adults aged ≥40 years undergoing upper gastrointestinal endoscopy for dyspepsia or other clinical indications (nonalarming and alarming symptoms both).\n2. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Known gastric malignancy.\n2. Prior gastric surgery (excluding H. pylori eradication).\n3. Contraindications to endoscopy or biopsy.\n4. Known hereditary gastric cancer syndromes.",true,"ALL","40 Years",{"count":20,"type":21},4000,"ESTIMATED","OBSERVATIONAL","To estimate the prevalence of histologically confirmed early gastric cancer (EGC) in an Indian multicentre cohort undergoing standardised high-quality upper gastrointestinal endoscopy. EGC is defined as gastric adenocarcinoma confined to the mucosa or submucosa (T1), irrespective of lymph node status, based on histopathology.",[25,26],"Gastric Adenocarcinoma","Early Gastric Cancer","NOT_YET_RECRUITING","2026-06-02",{"date":30,"type":31},"2026-06-04","ACTUAL",{"date":33,"type":21},"2026-07-01",{"date":35,"type":21},"2028-07-01",{"name":37,"class":38},"Asian Institute of Gastroenterology, India","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":39},"100576688","fluorescence-guided-laparoscopic-endoscopic-cooperative-sentinel-lymph-node-navigation-surgery-strategy-for-early-gastric-cancerideal-stage-2b-100576688","NCT06788548","Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer（IDEAL Stage 2b）","Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer: A Multicenter Randomized Controlled Trial Study","FLECSS","Inclusion Criteria:\n\n* 1\\) Patients aged 18-80 years, regardless of gender. 2) Patients with Eastern Cooperative Oncology Group (ECOG) score ≤ 2 and American Society of Anesthesiologists (ASA) score ≤ 2 who are candidates for a curative D2 gastrectomy.\n\n  3\\) Patients without prior gastrointestinal surgery, chemotherapy, or radiotherapy.\n\n  4\\) Patients with normal liver, kidney, heart, lung, and bone marrow function (GPT × 109 \u002FL, PLT\\>109 \u002FL).\n\n  5\\) Patients capable of understanding and adhering to the research protocol. 6) Patients who can provide written informed consent, either personally or through legal representative.\n\n  7\\) Patients with cT1N0M0 gastric cancer or after non-curative ESD resection, according to the UICC TNM staging system, 8th edition.\n\nExclusion Criteria:\n\n* 1\\) Patients with a contraindication for gastroscopy. 2) Patients with uncontrollable diseases, such as coagulation disorders, epilepsy, central nervous system diseases or mental disorders, cardiopulmonary insufficiency, unstable angina, myocardial infarction, a cerebrovascular accident that occurred within 6 months, and other surgical contraindications.\n\n  3\\) Patients unable to undergo general anesthesia or surgical treatment due to conditions related to other organs, or unwilling to undergo surgery.\n\n  4\\) Patients with gastric stump cancer, recurrent gastric cancer, multiple primary malignant tumors in the abdominopelvic cavity, or a history of other malignant tumors within the previous 5 years.\n\n  5\\) Pregnant or lactating women. 6) Participants enrolled in other clinical trials. 7) Patients with undeterminable tracer staining range or contraindications to tracer use.\n\n  8\\) Patients who fail to receive or fail ESD therapy. 9) Patients who meet the absolute indication of ESD.","18 Years","80 Years",{"count":51,"type":21},312,"INTERVENTIONAL",[54],"NA","The main treatment for early gastric cancer (EGC) include endoscopic submucosal dissection (ESD) and radical gastrectomy. However, appropriate treatment for patients who exceed the absolute indications and noncurative resection of ESD remains unestablished. Sentinel node navigation surgery (SNNS) enables limited lymph node resection, thereby facilitating function-preserving gastrectomy (FPG) and improving quality of life (QoL). SNNS seems to be the promising solution according to previous study, however evidence-based medicine was lacking. It is imperative to establish its safety and efficacy in patients with EGC. However, the optimal implementation of FPG remain unclear. Moreover, objective assessment of postoperative functional outcomes,remains limited.",[26],[26,58,59,60,61,62,63,64],"Sentinel Lymph Node","Basin Dissection","Laparoscopic surgery","Safety AND Efficacy","Fluorescence Guided","Laparoscopic-Endoscopic Cooperative Surgery","multicenter","RECRUITING","2026-05-06",{"date":68,"type":31},"2026-05-11",{"date":70,"type":31},"2024-02-03",{"date":72,"type":21},"2029-12-30",{"name":74,"class":38},"Beijing Friendship Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":39},"100635344","ai-model-for-early-gastric-cancer-diagnosis-using-endoscopic-imaging-100635344","NCT07551466","AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging","Development and Validation of an Explainable Artificial Intelligence Model for Early Gastric Cancer Diagnosis Using Multimodal Endoscopic Imaging","XAI-EGC","Inclusion Criteria:\n\n* Age ≥18 years\n* Suspicious gastric lesions identified on white-light imaging (WLI)\n* Preoperative biopsy indicating precancerous lesions (dysplasia or intraepithelial neoplasia) or adenocarcinoma, with preoperative magnifying endoscopy with narrow-band imaging (ME-NBI) performed\n* Patients meeting the absolute indications for endoscopic submucosal dissection (ESD) and who underwent ESD\n\nExclusion Criteria:\n\n* Non-adenocarcinoma histological types (e.g., lymphoma)\n* Patients who did not undergo ME-NBI examination or did not receive ESD\n* Lesions invading the muscularis propria or deeper layers\n* Missing or indeterminate postoperative histopathological results",{"count":84,"type":21},100,"Early gastric cancer (EGC) is often difficult to detect accurately during endoscopic examination due to subtle morphological features and variability among endoscopists. Artificial intelligence (AI) has shown promise in improving diagnostic performance; however, most existing models lack interpretability and rely on single-modality imaging.\n\nThis study aims to develop and evaluate an explainable multimodal artificial intelligence model for the diagnosis of early gastric cancer using endoscopic imaging. The model integrates features derived from white-light imaging and image-enhanced endoscopy, along with quantitative image features and clinical data, to improve diagnostic accuracy and provide interpretable decision support.\n\nThe primary outcome is the diagnostic performance of the AI model for detecting early gastric cancer, evaluated by area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity.\n\nThe results of this study are expected to provide evidence for the clinical utility of explainable AI in endoscopic diagnosis and support the development of reliable human-AI collaborative diagnostic systems.",[26],[26,88,89,90,91,92],"Artificial Intelligence","Multimodal Imaging","Endoscopic Imaging","Explainable AI","Deep Learning","2026-04-22",{"date":95,"type":31},"2026-04-24",{"date":97,"type":21},"2026-05-01",{"date":99,"type":21},"2027-02-01",{"name":101,"class":38},"The First Affiliated Hospital of Soochow University",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":39},"100631929","comparison-of-the-sensitivity-of-pcle-and-pathological-biopsy-for-gastric-mucosal-lesions-100631929","NCT07507071","Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions","Comparison of the Sensitivity of Probe-Based Confocal Laser Endomicroscopy and Pathological Biopsy for Gastric Mucosal Lesions","pCLE","Inclusion Criteria:\n\n* All patients aged 18-75 who underwent pCLE examination and received ESD treatmen.\n\nExclusion Criteria:\n\n* lack of pre-ESD pathological biopsy results, and ESD pathology indicated advanced gastric cancer.","75 Years",{"count":112,"type":21},169,"The pathological biopsy of gastric lesions, performed prior to endoscopic submucosal dissection (ESD), is crucial for differentiating the pathological nature of the lesions and guiding treatment decisions. However, due to the impact of biopsy sampling, the sensitivity of the pathological biopsy is not optimal.\n\nThe probe - based confocal laser endomicroscopy (pCLE) technique enables the real - time display of high-resolution microscopic images of the mucosal layer (with an amplification factor of up to 1000 times) through a slender optical fiber probe that can pass through the standard endoscope's working channel. It is an optical biopsy technique and has unique value in determining the pathological nature of gastric lesions.\n\nAs the Digestive Endoscopy Center of Shanghai Changhai Hospital is a national-level pCLE application demonstration center, it has prospectively collected numerous cases of pCLE examinations of gastric mucosal lesions.\n\nThe main purpose of this study is to retrospectively analyze these cases and compare the sensitivity and specificity of pathological biopsy and pCLE in differentiating the pathological nature of gastric mucosal lesions.",[26],[116,117,118,119,120],"Pathological biopsy","Early gastric cancer","High-grade intraepithelial neoplasia","Probe-based confocal Laser endomicroscopy","Endoscopic submucosal dissection","2026-03-29",{"date":123,"type":31},"2026-04-02",{"date":125,"type":21},"2026-03-30",{"date":127,"type":21},"2026-04-15",{"name":129,"class":38},"Changhai Hospital",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":137,"targetDuration":4,"studyType":52,"phases":139,"briefSummary":141,"conditions":142,"keywords":147,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":39},"100616957","phase-4-esomeprazole-plus-sucralfate-for-post-esd-ulcer-healing-100616957","NCT07312370","Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","Intravenous Esomeprazole Combined With Sucralfate Suspension for Ulcer Healing and Complication Prevention After Gastric Endoscopic Submucosal Dissection: A Prospective, Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years, male or female\n2. Diagnosed with early gastric cancer or high-grade intraepithelial neoplasia planned for gastric ESD\n3. Lesion location: Gastric corpus, antrum, or angle (cardiac lesions may be included but will require subgroup analysis)\n4. Successful en bloc resection achieved by ESD\n5. Post-ESD artificial ulcer diameter ≥2 cm\n6. Complete coagulation of all visible vessels during ESD procedure\n7. ECOG performance status 0-1\n8. Able to comply with follow-up visits and endoscopic examinations\n9. Voluntary participation with written informed consent\n\nExclusion Criteria:\n\n1. Previous gastric surgery history\n2. Active peptic ulcer disease (confirmed by pre-ESD endoscopy) within 1 month\n3. Recent upper gastrointestinal bleeding (within 1 month, excluding tumor-related bleeding)\n4. Severe heart, liver, or kidney dysfunction (Child-Pugh class C, NYHA class III-IV, or CKD stage 4-5)\n5. Coagulation disorders (INR \\>1.5 or platelet count \\\u003C50×10⁹\u002FL)\n6. Uncontrolled diabetes (HbA1c \\>9%)\n7. Known allergy or hypersensitivity to PPIs or sucralfate\n8. Use of PPIs, H2 receptor antagonists, or mucosal protective agents within 2 weeks prior to ESD\n9. Long-term anticoagulant therapy that cannot be discontinued (e.g., warfarin, direct oral anticoagulants)\n10. Long-term NSAIDs or aspirin (\\>100mg\u002Fday) that cannot be discontinued\n11. Unsuccessful complete (en bloc) resection (piecemeal resection)\n12. Intraoperative perforation\n13. Uncontrolled active bleeding during ESD\n14. Pregnancy or lactation\n15. Women of childbearing potential not using adequate contraception\n16. Concurrent participation in another clinical trial\n17. Any condition that, in the investigator's opinion, makes the patient unsuitable for study participation",{"count":138,"type":21},120,[140],"PHASE4","Endoscopic submucosal dissection (ESD) is an established treatment for early gastric cancer and precancerous lesions. Post-ESD artificial ulcers may lead to complications including delayed bleeding (3-15%) and prolonged healing. Current guidelines recommend high-dose proton pump inhibitors (PPIs), but evidence for additional mucosal protective agents remains limited.\n\nThis study aims to evaluate whether combining sucralfate suspension with standard intravenous esomeprazole therapy improves ulcer healing and reduces complications after gastric ESD compared to esomeprazole alone.\n\nThis is a prospective, randomized, controlled, outcome-assessor-blinded trial. A total of 120 patients undergoing gastric ESD will be randomly assigned 1:1 to receive either:\n\n* Intervention group: Intravenous esomeprazole 40mg twice daily (3 days) followed by oral esomeprazole 40mg once daily PLUS sucralfate suspension 1g twice daily for 8 weeks\n* Control group: Intravenous esomeprazole 40mg twice daily (3 days) followed by oral esomeprazole 40mg once daily for 8 weeks The primary outcome is ulcer reduction rate at 4 weeks post-ESD, assessed by endoscopy. Secondary outcomes include complete ulcer healing rate at 8 weeks, delayed bleeding rate, symptom scores, and safety parameters.\n\nThis study will provide high-quality evidence regarding the role of sucralfate as an adjunctive therapy for post-ESD ulcer management and may inform future clinical guidelines.",[26,143,144,145,146],"Gastric Dysplasia","Gastric Neoplasms","Peptic Ulcer With Haemorrhage","Gastric Ulcer",[148,149,150,151,152,153],"Endoscopic Submucosal Dissection","Gastric Cancer","Ulcer Healing","Proton Pump Inhibitor","Post-ESD Ulcer","Early Gastric Neoplasm","2026-03-19",{"date":156,"type":31},"2026-03-23",{"date":158,"type":21},"2026-04-20",{"date":160,"type":21},"2026-12-30",{"name":162,"class":38},"LanZhou University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":52,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":191},"100624153","evaluation-of-the-effectiveness-of-managing-chemotherapy-side-effects-using-epro-and-a-standardized-telenursing-program-for-cancer-patients-100624153","NCT07405931","Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Diagnosed with early or advanced gastric, lung, breast, or colon cancer\n* Starting first-cycle chemotherapy with a new anticancer agent\n* Able to use a smartphone without difficulty\n* Willing to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons\n* Individuals who cannot read, write, or understand Korean\n* Other individuals deemed inappropriate for participation by the investigators","19 Years",{"count":171,"type":21},414,[54],"This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.",[26,175,176,177,178,179,180,181],"Advanced Gastric Cancer","Early Lung Cancer","Advanced Lung Cancer","Early Breast Cancer","Advanced Breast Cancer","Early Colon Cancer","Advanced Colon Cancer","2026-02-08",{"date":184,"type":31},"2026-02-12",{"date":186,"type":31},"2025-07-09",{"date":188,"type":21},"2026-09",{"name":190,"class":38},"Ulsan University Hospital",5,{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":52,"phases":202,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":39},"100615622","sentinel-node-resection-with-or-without-lecs-after-noncurative-esd-for-egc-100615622","NCT07295002","Sentinel Node Resection With or Without LECS After Noncurative ESD for EGC","COmpletion Sentinel Node Resection With or Without Minimally invAsive and Endoscopic Cooperative Surgery Following noncuRative Endoscopic Submucosal Dissection for Early Gastric Cancer","Co-SNARE","Inclusion Criteria:\n\n* EGC previously treated with ESD according to current guidelines (differentiated adenocarcinoma, not ulcerative, of any size, differentiated adenocarcinoma ulcerative \\\u003C\u002F=3cm, undifferentiated adenocarcinoma not ulcerative \\\u003C\u002F=2cm)\n* Non curative resection\n\n  * Lymphovascular invasion\n  * Non-radical resection vertical margin\n  * deep submucosal invasion\n* Signed informed consent\n\nExclusion Criteria:\n\n* Location within 2 cm from cardia or pylorus\n* Non-curative resection with only non-radicality horizontal margin\n* Inoperative because of severe comorbidities\n* Previous radiotherapy to the upper abdomen\n* Pregnancy\n* Allergy to ICG\n* Inability to provide informed consent due to cognitive impairment, language barrier, or other reasons impairing understanding and autonomous decision-making.",{"count":201,"type":21},10,[54],"For patients with non-curative resection after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC), complementary surgery is generally recommended. However, about 2\u002F3 of patients have no remaining tumor in the stomach or regional lymph nodes. In this trial, Indocyanine Green (ICG)-guided lymphadenectomy with or without laparoscopic and endoscopic cooperative surgery (LECS) will be tested as a less invasive alternative in such cases. For patients with a primary radically resected EGC, ICG-guided lymphadenectomy alone will be performed. For patients with deep-margin positive EGC, ICG-guided lymphadenectomy and LECS will be performed, in order to ensure both local tumor control in the stomach and in regional nodes.",[26],[206,207],"sentinel node-resection","minimal invasive surgery","2025-12-15",{"date":210,"type":31},"2025-12-19",{"date":212,"type":21},"2026-01-01",{"date":214,"type":21},"2029-10-01",{"name":216,"class":217},"Region Stockholm","OTHER_GOV",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":39},"100612466","distribution-characteristics-of-helicobacter-pylori-100612466","NCT07253948","Distribution Characteristics of Helicobacter Pylori","Distribution Characteristics of Helicobacter Pylori in Different Gastritis and Early Gastric Cancer States Using Immunohistochemical Staining","Inclusion Criteria:\n\n* age 18-80 years\n* received H. pylori immunohistochemical testing at our center and tested positive.\n\nExclusion Criteria:\n\n* biopsies not collected from both the greater and lesser curvatures of the gastric antrum and body\n* history of stomach surgery\n* suspected autoimmune gastritis under endoscopy\n* liver cirrhosis\n* severe comorbidities such as advanced cancer or renal failure\n* advanced gastric cancer or gastric lymphoma",{"count":226,"type":21},231,"This study aimed to analyze the distribution characteristics of Helicobacter pylori（H. pylori） in varying stages of atrophic gastritis and early gastric cancer using immunohistochemical staining, with the goal of providing guidance for the early screening of gastric cancer.\n\nA retrospective analysis was conducted on gastric biopsy cases that underwent H. pylori immunohistochemical staining at our center from March 1, 2023, to August 15, 2025. Cases were classified into non-atrophic and atrophic groups based on the presence or absence of gastric atrophy. All cases were further divided into non-open and open atrophy groups and additionally into early gastric cancer and non-cancer groups. The distribution of H. pylori across subgroups was compared, and multivariate analyses were performed to identify risk factors associated with the development of early gastric cancer.",[229,26],"Helicobacter Pylori",[231,232,233,234],"Helicobacter pylori","Immunohistochemical staining","Atrophic gastritis","Early gastric cancer screening","2025-11-26",{"date":237,"type":31},"2025-11-28",{"date":239,"type":31},"2025-10-22",{"date":241,"type":21},"2025-12-31",{"name":243,"class":38},"Jilin University",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":251,"maxAge":49,"enrollmentInfo":252,"targetDuration":4,"studyType":52,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100283322","a-predictive-model-based-on-narrow-band-imaging-for-early-gastric-cancerous-lesions-100283322","NCT02968069","A Predictive Model Based on Narrow Band Imaging for Early Gastric Cancerous Lesions","Development and Validation of a Predictive Model for Early Gastric Cancerous Lesions Under Endoscopic Observation","Inclusion Criteria:\n\n* Suspected of having a cancerous lesions\n* The age of patients is from 40-80 years\n* Patients must undergo esophagogastroduodenoscopy\n\nExclusion Criteria:\n\n* Clinical diagnosis of advanced gastric cancer\n* Acute upper gastrointestinal bleeding\n* Severe systemic diseases\n* Refuse to attend the study","20 Years",{"count":253,"type":21},300,[54],"Without high diagnostic efficacy of endoscopic forceps biopsy (EFB) and with low diagnostic efficacy of narrow band imaging (NBI) in novice endoscopists and endoscopists of community hospitals in China, it is urgent to improve diagnostic efficacy for gastric cancerous lesions.The investigators will conduct a study to develop and validate a diagnostic model based on NBI for early gastric cancerous lesions under endoscopic observation.",[26],"2025-09-27",{"date":259,"type":31},"2025-10-02",{"date":261,"type":21},"2025-10-10",{"date":263,"type":21},"2026-10-01",{"name":265,"class":38},"Shanghai Jiao Tong University School of Medicine",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":39},"100413599","clinical-application-of-genetic-sequencing-of-early-gastric-cancer-and-gastric-adenoma-patients-100413599","NCT04665687","Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients","Clinical Sequencing Project for Early Gastric Cancer and Precancerous Gastric Adenoma Patients for Personalized Cancer Clinic","Inclusion Criteria:\n\n1. Those who are over the age of 19\n2. Those who were histologically confirmed with early gastric cancer or precancerous gastric adenoma\n3. Patients with early gastric cancer or precancerous gastric adenoma falling under the above criteria who have excess tissue stored from previous non-research purpose biopsy\u002Fendodoscopic removal for treatment and diagnosis\n4. Those whose life expectancy is more than 3 months\n5. Those who have voluntarily consented to participate in this clinical trial\n\nExclusion Criteria:\n\n1. Those who will not yield enough samples\n2. Those who are considered inappropriate for this study in the discretion of the researchers","100 Years",{"count":275,"type":21},1730,"Because advanced gastric cancer shows poor prognosis, it is important to detect early gastric cancer or precancerous gastric adenoma patients who have a cure rate of 95% or more. Moreover, a large part of early gastric cancer can be completely resected by endoscopic resection, thus ensuring a very high quality of life for patients. However, there are currently no markers that can be used for diagnosis of early gastric cancer or gastric adenoma. In addition, the biggest problem after endoscopic resection of early gastric cancer is metachronous recurrence of the cancer, which requires repeated endoscopic resection or additional surgical gastrectomy. However, there are no discovered markers for prediction of recurrence.\n\nLiquid biopsy is a method of obtaining body fluids such as gastric juice or effusion through an endoscopic inlet during gastroscopy or colonoscopy and blood. Based on the advanced analysis method, liquid biopsy reveals more genetic information than tissue biopsy. Therefore, it is highly likely to become an essential factor in future personalized medicine. Therefore, this study was designed to identify whether tumor's molercular profiling based on tissue or blood could be used for prediction of prognosis and diagnosis of early gastric cancer and precancerous gastric adenoma.",[26,278],"Gastric Adenoma","2025-09-06",{"date":281,"type":31},"2025-09-12",{"date":283,"type":31},"2020-12-17",{"date":285,"type":21},"2031-12-31",{"name":287,"class":38},"Samsung Medical Center",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":52,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":39},"100590044","magnetic-guided-counetrtraction-during-endoscopic-submucosal-dissection-100590044","NCT06962293","Magnetic Guided Counetrtraction During Endoscopic Submucosal Dissection","Magnetic Anchor Guided - Endoscopic Submucosal Dissection (MAG-ESD) for Gastric and Colorectal Superficial Lesions - a Pilot Study","Inclusion Criteria:\n\n* Patient with superficial gastric or colorectal lesions, scheduled for endoscopic submucosal dissection (ESD).\n\nExclusion Criteria:\n\n1. Patient who refused to participate\n2. Other cases deemed by the examining physician as unsuitable for safe treatment\n\n   The robotic magnetic countertraction system consist of a strong permanent magnet which always have a strong magnetic field in its surrounding. Therefore, we follow the MRI precautions for the strict safety measurement:\n3. Patient who had a cardiac pacemaker.\n4. Patient who had any metallic implant or device, such as drug pump, stent, etc.\n5. Patient who has or had any metal fragments in eye or any other part of body, or had ever worked with metal.","85 Years",{"count":297,"type":21},20,[54],"Endoscopic submucosal dissection (ESD) is a technique that allows curative treatment of early gastrointestinal neoplasia with organ preservation. However, it is a technically demanding procedure. Tissue traction plays a vital role in facilitating the visualization of the cutting line and the submucosal vessels, which usually only relies on the hood attached to the tip of the endoscope. However, when dealing with flat or large lesions, the absence of reliable traction in ESD contributes to its technical complexity and prolongs procedure duration. Various traction devices and techniques have been developed to provide tension for the dissection plane and optimal visibility during ESD. Most of these only provide static traction from a fixed angle, thus the effect of traction diminishes when the dissection continues.\n\nIn contrast to the aforementioned traction methods, magnetic traction offers the ability to externally manipulate an internal magnetic retractor, simplifying the internal workspace. The proposed magnetic retractor is composed of a detachable clip from an hemoclip is affixed to a magnetic element. By adjusting the position of the external magnetic source, the magnetic retractor automatically couples and aligns with it, enabling simultaneous dynamic directional control during the ongoing ESD operation. A novel robotic magnetic countertraction system was developed (MAG-ESD). The system consists of two sections: an external permanent magnetic source and the disposable magnetic retractor. The external permanent magnetic source is composed by a large external permanent magnet (EPM) which held by robot arm to externally control the locomotion of the magnetic retractor within patient. The disposable magnetic retractor is a consumable surgical instrument that modified from a commercial hemoclip, which has small magnets hangs on the clip legs. The design of the disposable magnetic retractor eliminates the need for endoscope withdrawal which can be inserted through the instrument channel from the handle during ESD operations, like other common instruments. In the current pilot study, the novel MAG-ESD counetrtraction system would be tested in 20 patients who undergo gastric and colonic ESD, with the aim of evaluating the system efficacy and safety.",[26,301],"Colon Neoplasia",[303,304],"endoscopic submucosal dissection","magnetic retractor","2025-04-30",{"date":307,"type":31},"2025-05-08",{"date":309,"type":21},"2025-05-09",{"date":311,"type":21},"2026-06-30",{"name":313,"class":38},"Chinese University of Hong Kong",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":321,"targetDuration":4,"studyType":52,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":39},"100573597","safety-and-efficacy-of-traction-robot-assisted-endoscopic-submucosal-dissection-for-early-gastric-cancer-100573597","NCT06748352","Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer","Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer: a Pilot Randomized Controlled Study","Inclusion Criteria:\n\n* Patients aged 18-80.\n* Patients with pathologically verified high-grade intraepithelial neoplasia (HGIN) or intramucosal carcinoma of the stomach.\n\nExclusion Criteria:\n\n* Patients have lesions with confirmed or potential deep submucosal invasion or lymph node metastasis.\n* Patients with severe underlying diseases precluding endotracheal intubation, general anesthesia, or surgery.\n* Patients have a history of gastric malignancy with previous radiotherapy or operative treatment leading to changes in gastric structure.\n* Patients have lesions with local recurrence after endoscopic resection.\n* Patients unable to obtain informed consent.",{"count":322,"type":21},50,[54],"The goal of this clinical trial is to investigate whether the flexible auxiliary single-arm transluminal endoscopic robot (FASTER) system can improve the safety of the endoscopic submucosal dissection (ESD). It will also evaluate the efficacy of the system, such as whether it could reduce the procedure time and so on. The main questions it aims to answer are:\n\nDoes the use of the FASTER system reduce the number of muscular injuries, improving the safety of the ESD procedure? Does the use of the FASTER system reduce the procedure and dissection time, improving the efficacy of the ESD procedure? Researchers will compare FASTER-assisted ESD and conventional ESD to evaluate the safety and efficacy of the FASTER system.\n\nParticipants will:\n\nBe randomly assigned to the group with ESD using the traditional procedure or to the group with ESD assisted by the FASTER system.\n\nKeep a diary of their symptoms after the procedure. ESD has gained widespread acceptance as the standard method for treating early-stage gastrointestinal cancers. Adequate exposure of the submucosa layer through effective tissue traction is vital for the safe and effective performance of ESD. The FASTER system is designed to overcome this technical difficulty.",[26,148,326],"Robot Surgery","2024-12-21",{"date":329,"type":31},"2024-12-27",{"date":331,"type":21},"2024-12-30",{"date":333,"type":21},"2025-03-01",{"name":335,"class":38},"Shandong University",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":110,"enrollmentInfo":343,"targetDuration":4,"studyType":52,"phases":345,"briefSummary":346,"conditions":347,"keywords":351,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":39},"100546016","comparison-of-pcle-and-eb-in-gastric-lesion-diagnosis-100546016","NCT06389448","Comparison of pCLE and EB in Gastric Lesion Diagnosis","Comparison of Probe-based Confocal Laser Endomicroscopy and Traditional Endoscopic Biopsies in the Diagnosis of Gastric Cancer and Precancerous Lesions: a Prospective Multicenter Comparative Study","Inclusion Criteria:\n\n* Over 18 years old and under 75 years old;\n* Patients with pathological diagnosis of LGIN, HGIN or early gastric cancer after conventional endoscopy biopsy, whose lesion has clear boundaries under endoscopic observation and is to be admitted for ESD surgery;\n* Patients who meet the indications for endoscopic resection of early gastric cancer, or LGIN patients who intend to undergo ESD surgery;\n* Patients who are able to provide pathological specimens\u002Fsections of previous endoscopic biopsy (in principle, it should be a case of this center).\n\nExclusion Criteria:\n\n* Patients with advanced gastric cancer or previous gastrectomy;\n* Patients with severe cardiopulmonary dysfunction, liver cirrhosis, renal dysfunction, acute gastrointestinal bleeding, esophageal-gastro varices, and coagulation disorders;\n* Patients who have a positive result in the fluorescein sodium allergy test;\n* Pregnant and lactating women;\n* Patients who have psychiatric disorders and are unable to cooperate with endoscopy or sign informed consent.",{"count":344,"type":21},366,[54],"This is a prospective multicenter comparative study, aiming to compare probe-based confocal laser endomicroscopy (pCLE) and endoscopic biopsies in the diagnosis of the whole specific gastric lesion especially for distinguishing low grade intraepithelial neoplasia (LGIN) from high grade intraepithelial neoplasia (HGIN) and create an endoscopic image database for the follow-up research.",[348,349,26,350],"Low Grade Intraepithelial Neoplasia","High Grade Intraepithelial Neoplasia","Gastric Intraepithelial Neoplasia",[352,353,354,355],"confocal laser endomicroscopy","endoscopic biopsy","Intraepithelial Neoplasia","gastric cancer","2024-05-06",{"date":358,"type":31},"2024-05-07",{"date":360,"type":31},"2024-04-11",{"date":362,"type":21},"2026-10",{"name":364,"class":38},"Huazhong University of Science and Technology",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":17,"minAge":251,"maxAge":49,"enrollmentInfo":372,"targetDuration":4,"studyType":52,"phases":374,"briefSummary":375,"conditions":376,"keywords":377,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":391},"100514467","feasibility-study-of-sentinel-navigation-surgery-in-early-gastric-cancer-using-fluorescence-senorita4-100514467","NCT05978882","Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4)","Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4 Trial)","Inclusion Criteria:\n\n* single lesion of adenocarcinoma in preoperative endoscopic biopsy clinical stage T1N0 in the preoperative evaluation of endoscopy and computed tomography\n* tumor size: less than 3cm\n* location: 2cm far from the pylorus or cardia\n* aged 20 to 80\n* ECOG 0 or 1\n* patient who signed the agreement\n* patient who is suspected to underwent laparoscopic or robotic gastrectomy\n\nExclusion Criteria:\n\n* indication of endoscopic submucosal resection\n* inoperable due to poor cardiac, and pulmonary function\n* pregnant\n* having allergic reaction, previous upper abdominal surgery except laparoscopic cholecystectomy, previous radiation therapy to upper abdomen\n* diagnosed as malignancy within 5 years except carcinoma in situ of cervix cancer and thyroid cancer",{"count":373,"type":21},203,[54],"SENORITA 1 trial showed laparoscopic sentinel lymph node biopsy and stomach preserving surgery in early gastric cancer can increase the quality of life. (Ryu KW et al. JCO 2022) The radioactive isotope is difficult to use because of the hazard of radiation and shortage of materials. The aim of this study is to investigate whether laparoscopic sentinel lymph node biopsy and stomach-preserving surgery using only fluorescence is feasible.",[26],[117,378,379,380,381],"Sentinel lymph node","Fluorescence","Stomach-preserving surgery","Quality of life","2023-07-31",{"date":384,"type":31},"2023-08-07",{"date":386,"type":21},"2023-08-17",{"date":388,"type":21},"2030-12-31",{"name":390,"class":217},"National Cancer Center, Korea",7,{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":110,"enrollmentInfo":398,"targetDuration":4,"studyType":52,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":39},"100464148","the-relationship-between-scar-formation-and-esd-depth-in-therapy-for-gastric-carcinoma-100464148","NCT05323929","The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma","Inclusion Criteria:\n\n* Patients older than 18 years old and younger than 75 years old.\n* Early gastric cancer (T1a stage) diagnosed by gastroscopy or ultrasonography, differentiated and no ulcer; or early gastric cancer (T1a stage), differentiated with ulcer, lesion diameter \\\u003C3cm; or early gastric cancer (T1a stage), undifferentiated and No ulcer, lesion diameter \\\u003C2cm.\n* Pathological diagnosis of gastric cancer.\n* No further treatment is required.\n* Patients diagnosed for the first time without other serious gastrointestinal diseases.\n\nExclusion Criteria:\n\n* Those who did not comply with the test requirements, obviously violated this protocol, or switched to other protocols in the middle of treatment.\n* Advanced gastric cancer; or undifferentiated gastric cancer lesions \\> 2 cm in diameter; or differentiated gastric cancer with ulcer lesions \\> 3 cm in diameter.\n* Coagulation disorders.\n* Serious heart, liver, kidney and other diseases, can not tolerate ESD treatment.\n* Patients with gastric cancer complications such as gastrointestinal bleeding and perforation that need emergency treatment.\n* Patients with distant metastasis.\n* Patients with other tumors, patients with a history of malignant tumors (except early carcinoma in situ.\n* The patient himself requests to withdraw from the trial.\n* The researcher believes that the patient is not suitable to participate in this study.",{"count":399,"type":21},200,[54],"This study is a single-center, prospective, group-controlled clinical trial, aiming to clarify the relationship between the depth of dissection and scar formation in the treatment of early gastric cancer by ESD, and to provide high-quality evidence-based medicine for the treatment of early gastric cancer.",[26,148],"2022-04-12",{"date":405,"type":31},"2022-04-14",{"date":407,"type":31},"2022-01-01",{"date":409,"type":21},"2027-12-31",{"name":411,"class":38},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":16,"sex":17,"minAge":251,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":430,"locationsCount":39},"100461674","screening-for-early-gastric-cancer-in-shaanxi-province-100461674","NCT05291728","Screening for Early Gastric Cancer in Shaanxi Province","Inclusion Criteria:\n\n* Local resident over 20 years old.\n* Obtain verbal informed consent of the subject.\n\nExclusion Criteria:\n\n* Refused to participate in this research project.\n* Questionnaires or serological tests for helicobacter pylori antibodies were not completed.\n* This study was not completed due to other reasons.",{"count":419,"type":21},12500000,"This study collect the relevant data of local residents over 20 years old in 11 regions of Shaanxi Province, The basic information of the subjects was collected by filling in the questionnaire, and serum helicobacter pylori antibody detection was completed at the same time. The expert group determined the high-risk population of gastric cancer after comprehensive evaluation. All the high-risk population of gastric cancer without contraindications underwent electronic gastroscopy in the designated hospital after signing the informed consent. By collecting and analyzing data, early gastric cancer screening was completed and a new gastric cancer risk assessment model was established to evaluate the prevalence of dyspepsia, gastroesophageal reflux disease and precancerous lesions in the natural population of Shaanxi Province, as well as helicobacter pylori infection, radical treatment and recurrence rate.",[26],[423],"early GC,Hp infection,FD, GERD , precancerous lesions","2022-03-13",{"date":426,"type":31},"2022-03-23",{"date":428,"type":31},"2020-10-01",{"date":263,"type":21},{"name":431,"class":38},"Second Affiliated Hospital of Xi'an Jiaotong University",{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":110,"enrollmentInfo":439,"targetDuration":4,"studyType":52,"phases":441,"briefSummary":443,"conditions":444,"keywords":447,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":39},"100437223","phase-2-indocyanine-green-tracer-using-in-laparoscopic-distal-gastrectomy-for-early-gastric-cancer-100437223","NCT04973475","Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer","Prospective Clinical Trials on Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy With Lymph Node Dissection for Early Gastric Cancer","Inclusion Criteria:\n\n1. Age from 18 to 75 years\n2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy\n3. Clinical stage tumor T1 (cT1), N0\u002F+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Eighth Edition. Preoperative staging was made by conducting mandatory computed tomography (CT) scans and an optional endoscopic ultrasound\n4. No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby in the preoperative examinations\n5. Tumor located in the lower third of the stomach, expected to receive radical distal gastrectomy\n6. Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)\n7. American Society of Anesthesiology score (ASA) class I, II, or III\n8. Written informed consent\n\nExclusion Criteria:\n\n1. Women during pregnancy or breast-feeding\n2. Severe mental disorder\n3. History of previous upper abdominal surgery (except laparoscopic cholecystectomy)\n4. History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection\n5. Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging\n6. History of other malignant disease within past five years\n7. History of previous neoadjuvant chemotherapy or radiotherapy\n8. History of unstable angina or myocardial infarction within past six months\n9. History of cerebrovascular accident within past six months\n10. History of continuous systematic administration of corticosteroids within one month\n11. Requirement of simultaneous surgery for other disease\n12. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer\n13. Forced expiratory volume in 1 second (FEV1)\\\u003C50% of predicted values\n14. Rejection of laparoscopic resection\n15. Preoperatively confirmed tumors invading the dentate line or duodenum\n16. History of allergy to iodine agents\n17. Tumor located in the upper third of the stomach, expected to receive radical total gastrectomy",{"count":440,"type":21},180,[442],"PHASE2","This study aims to explore the value of indocyanine green (ICG) in laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer.The patients with early gastric adenocarcinoma (cT1, N-\u002F+, M0) will be studied.",[26,445,446],"Indocyanine Green","Lymph Node Dissection",[448,449,450,446],"Stomach Neoplasms","Indocyanine Green Tracer","Laparoscopic Distal Gastrectomy","2021-07-13",{"date":453,"type":31},"2021-07-22",{"date":455,"type":21},"2021-07",{"date":457,"type":21},"2026-07",{"name":459,"class":38},"Fujian Medical University",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":52,"phases":468,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":39},"100351583","endoscopic-submucosal-dissection-versus-surgery-in-the-treatment-of-early-gastric-cancer-100351583","NCT03857737","Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer","A Study Which Compares the Long Term and Short Term Outcomes Between Endoscopic Submucosal Dissection and Surgery in the Treatment of Early Gastric Cancer","Inclusion Criteria:\n\n* Clinically diagnosed as early gastric cancer\n* Willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer\n\nExclusion Criteria:\n\n* Advanced stage gastric cancer\n* Not willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer\n* Not willing to participate in this study",{"count":253,"type":21},[54],"In this study, patients who are going to undergo endoscopic submucosal dissection (ESD) or surgery for early gastric cancer will be enrolled and divided into ESD group and Surgery group according to the procedure they go through. The patients will be followed up for at least 5 years after ESD or surgery. Esophagogastroduodenoscopy (EDG) and biopsy will be performed 3 months and then 6 months after ESD or surgery. Thereafter, EDG will be performed along with biopsy and abdominal computed tomography annually up to 5 years. Patients' data such as age, sex, clinical diagnosis, achievement of en-bloc resection, pathological outcomes, complications and survival condition will be prospectively collected. Statistical methods such as Student's t-test, the chi-square test, the Kaplan-Meier method and the log-rank test will be used to compare the short term and long term outcomes between the ESD group and the surgery group.",[26],[472,303,473],"early gastric cancer","surgery","2019-02-27",{"date":476,"type":31},"2019-02-28",{"date":478,"type":21},"2019-03-01",{"date":480,"type":21},"2029-12-31",{"name":482,"class":38},"Peking University Third Hospital"]